Mobocertinib given breakthrough designation therapy status for non-small-cell lung cancer with EGFR Exon 20 Insertion Mutations in the US

Breakthrough designation was based on the overall response rate and the long-term benefit seen in in a Phase 1/2 study evaluating this small-molecule tyrosine kinase inhibitor specifically designed to selectively target EGFR and HER2 exon 20 insertion mutations.


Biospace Inc.